Christopher C. Nessel

Statistics

Publications

Citations

16.3K

H-Index

Active since

1998

Affiliations

Edinburgh Royal Infirmary(Current)

Harvard University

University of Edinburgh

Massachusetts General Hospital

Bayer (United States)

Christopher C. Nessel is an author at Edinburgh Royal Infirmary specializing in cardiovascular pharmacotherapy, pharmacotherapy, and clinical pharmacology.

ORCID

Publications per year

1998–2019

Publications

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

Keith A.A. Fox, Jonathan P. Piccini, Daniel Wojdyla et al. · European Heart Journal · 2011 · 614 citations

Medicine, Cardiology, Pharmacotherapy +14

Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation

Jonathan P. Piccini, Susanna R. Stevens, Yuchiao Chang et al. · Circulation · 2012 · 499 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Jonathan L. Halperin, Graeme J. Hankey, Daniel Wojdyla et al. · Circulation · 2014 · 429 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial

Benjamin A. Steinberg, Anne S. Hellkamp, Yuliya Lokhnygina et al. · European Heart Journal · 2014 · 356 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

1–5 of 52